Amicus Therapeutics (NASDAQ:FOLD) just reported results for the second quarter of 2024.
- Amicus Therapeutics reported earnings per share of 6 cents. This was above the analyst estimate for EPS of -5 cents.
- The company reported revenue of $126.67 million.
- This was 4.31% better than the analyst estimate for revenue of $121.43 million.